← Leaderboards
Shwetal V Mehta
Dana-Farber Cancer Inst
$3,080,724
Attributed
$4,266,340
Total exposure
4
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $629.6K · FY2006–25$1M$750K$500K$250K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,266,340 · 4
By mechanism
R01$3,536,783 · 2
R56$580,194 · 1
F32$149,363 · 1
Top collaborators
- Nhan L Tran4 shared
Most similar at Dana-Farber Cancer Inst
Same institution · by research overlap
- Dipanjan Chowdhury$12,356,287
- Santosh Kesari$1,550,298
- David Kozono$1,824,190
- Wilfred Ngwa$5,702,695
- Diana Shi$1,011,306
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsMolecularBrainMediatingComplexPhosphorylationMalignant NeoplasmsReceptor Protein-Tyrosine KinasesResistanceTargeted TreatmentTumorMouse ModelOncogenicEpidermal Growth Factor ReceptorGliomaTranscription FactorSignal TransductionGlioblastomaAffectProteinsKnock-DownGenesAnimalsNerve Stem Cell
Grant awards (12)
STAT5/OLIG2 regulation of GBM therapeutic resistance and recurrence - Resubmit 3.22$595,640
R01 · FY2025 · CA
STAT5/OLIG2 regulation of GBM therapeutic resistance and recurrence - Resubmit 3.22$565,756
R01 · FY2024 · CA
STAT5/OLIG2 regulation of GBM therapeutic resistance and recurrence - Resubmit 3.22$629,642
R01 · FY2023 · CA
Enhancing Treatment Response by Leveraging STAT5-OLIG2 signaling in GBM$580,194
R56 · FY2020 · NS
Targeting Olig2 Co-regulators for Malignant Glioma Therapy$349,149
R01 · FY2019 · NS · contact PI
Targeting Olig2 Co-regulators for Malignant Glioma Therapy$349,149
R01 · FY2018 · NS · contact PI
Targeting Olig2 Co-regulators for Malignant Glioma Therapy$349,149
R01 · FY2017 · NS · contact PI
Targeting Olig2 Co-regulators for Malignant Glioma Therapy$349,149
R01 · FY2016 · NS · contact PI
Targeting Olig2 Co-regulators for Malignant Glioma Therapy$349,149
R01 · FY2015 · NS · contact PI
Downstream Targets of Olig 2$50,139
F32 · FY2008 · NS · contact PI
Downstream Targets of Olig 2$50,428
F32 · FY2007 · NS · contact PI
Downstream Targets of Olig 2$48,796
F32 · FY2006 · NS · contact PI